SAN FRANCISCO, May 16, 2014 /PRNewswire/ -- Nektar
Therapeutics' (Nasdaq: NKTR) is scheduled to present at the
upcoming UBS 2014 Global Healthcare Conference in New York at the Sheraton New York Hotel on
Tuesday, May 20, 2014 at 2:30 p.m. Eastern time.
The presentation will be accessible via a Webcast through a link
posted on the Investor Relations, Events Calendar section of the
Nektar website: http://www.nektar.com. This Webcast will be
available for replay until June 20,
2014.
About Nektar
Nektar Therapeutics (NASDAQ: NKTR) is a biopharmaceutical
company developing novel therapeutics based on its PEGylation and
advanced polymer conjugation technology platforms. Nektar has a
robust R&D pipeline of potentially high-value therapeutics in
oncology, pain and other therapeutic areas. In the area of pain,
Nektar has an exclusive worldwide license agreement with
AstraZeneca for naloxegol (NKTR-118), an investigational drug
candidate, which has been filed for regulatory approvals in the
U.S., Europe and Canada as a once- daily, oral tablet for the
treatment of opioid-induced constipation. This agreement also
includes NKTR-119, an earlier stage development program that is a
co-formulation of naloxegol and an opioid. NKTR-181, a novel
mu-opioid analgesic molecule for chronic pain conditions, has
completed Phase 2 development in osteoarthritis patients with
chronic knee pain. NKTR-171, a new sodium channel blocker being
developed as an oral therapy for the treatment of peripheral
neuropathic pain, is in Phase 1 clinical development. In oncology,
etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3
clinical study (the BEACON study) for the treatment of metastatic
breast cancer and is also in Phase 2 studies for the treatment of
ovarian, colorectal, lung and brain cancers. In anti-infectives,
Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare
as an adjunctive treatment for intubated and mechanically
ventilated patients with Gram-negative pneumonia. Additional
development-stage products that leverage Nektar's proprietary
technology platform include Baxter's BAX 855, a long-acting PEGylated
rFVIII program, which is in Phase 3 clinical development for
patients with hemophilia A.
Nektar's technology has enabled eight approved products in the
U.S. or Europe through
partnerships with leading biopharmaceutical companies, including
UCB's Cimzia® for Crohn's disease and rheumatoid
arthritis, Roche's PEGASYS® for hepatitis C and Amgen's
Neulasta® for neutropenia.
Nektar is headquartered in San
Francisco, California, with additional operations in
Huntsville, Alabama and
Hyderabad, India. Further
information about the company and its drug development programs and
capabilities may be found online at http://www.nektar.com.
Media Contact: Jennifer Ruddock,
415-482-5585
SOURCE Nektar Therapeutics